🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Vishnu Kumarasamy

Roswell Park Comprehensive Cancer Center

ORCID: 0009-0008-2021-0730
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer”.

The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

Frontiers in Oncology(2023)10.3389/fonc.2022.966441
N/A
0.483DataRank · unranked
24 citations

Ahmed M. Elshazly, Nipa Patel, Liliya Tyutyunyk‐Massey, Tammy H. Tran, Vishnu Kumarasamy +3 more

Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy

Trends in cancer(2022)10.1016/j.trecan.2022.04.006
N/A
0DataRank · unranked
51 citations

Vishnu Kumarasamy, Ioannis Sanidas, Erik S. Knudsen, Agnieszka K. Witkiewicz

Adefovir Dipivoxil as a Therapeutic Candidate for Medullary Thyroid Carcinoma: Targeting RET and STAT3 Proto-Oncogenes

Cancers(2023)10.3390/cancers15072163
N/A
0DataRank · unranked
6 citations

Vishnu Kumarasamy, Sahar S. Alghamdi, Rasha Saad Suliman, Khalid Bin Saleh, Mohammed Alrashed +3 more

Pharmacologically targeting KRAS G12D in PDAC models: tumor cell intrinsic and extrinsic impact

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.18.533261
N/A
0DataRank · unranked
3 citations

Costakis Frangou, Jianxin Wang, Yin Wan, Andrew Dynka, Hanna R. Rosenheck +5 more

The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer

Cancer Research(2024)10.1158/0008-5472.can-23-2504
N/A
0DataRank · unranked
48 citations

Jianxin Wang, Costakis Frangou, Yin Wan, Andrew Dynka, Hanna R. Rosenheck +5 more

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle

Nature Communications(2025)10.1038/s41467-025-56674-4
N/A
0DataRank · unranked
35 citations

Jianxin Wang, Michelle Roti, Yin Wan, Adam P. Dommer, Hanna R. Rosenheck +11 more

RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress

Cell Death Discovery(2025)10.1038/s41420-025-02864-4
N/A
0DataRank · unranked
2 citations

Subrahmanya Anirudh Kaligotla Venkata, Erik S. Knudsen, Vishnu Kumarasamy, Agnieszka K. Witkiewicz

CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities

Cell Reports(2022)10.1016/j.celrep.2022.110448
N/A
0DataRank · unranked
134 citations

Vishnu Kumarasamy, Ram Nambiar, Joel D. Pearson, Paris Vail, Hanna R. Rosenheck +8 more

Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma

Molecular Cancer(2025)10.1186/s12943-025-02408-5
N/A
0DataRank · unranked
3 citations

Kennedy S. Humphrey, Eduardo Cortes Gomez, Jianxin Wang, Vishnu Kumarasamy, Yin Wan +7 more